Royalty Pharma holder plans $8.17M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) is the issuer of 150,000 Class A ordinary shares that SCH Investment Partners LLC reported for sale, with an approximate sale date of June 23, 2026, and an aggregate market value of $8,166,766.13. The shares were acquired from the issuer in a private transaction on February 14, 2025.
The sale is described as being made in connection with a selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c). The form lists SCH Investment Partners LLC's relationship to the issuer as Officer. Christopher Hite signed the notice.
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
selling plan financial
Aggregate Market Value financial
private transaction financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.